1. Varun Beverages (VBL):

The stock of this food & beverages company rose 3.8% over the past week, fueled by rising temperatures and a refreshing Q1CY26 performance. VBL’s Q1 net profit jumped 20.1% YoY to Rs 872.4 crore, led by lower inventory and deferred tax expenses. Revenue climbed 18.5% to Rs 6,765.1 crore, helped by higher net realisation and sales. The stock features in a screener of companies that have outperformed their industry over the past month.

VBL is going big in Africa. It recently finalized its 100% acquisition of South African beverage firm Twizza and signed a deal to buy Crickley Dairy for approximately Rs 1,315 million. This move marks a major pivot from its core PepsiCo franchise, diversifying the portfolio into the high-growth dairy and juice-based drink segments.

Its quarterly net profit and revenue surpassed Trenlyne’s Forecaster estimates by 15% and 11%, respectively. The strong growth was driven by robust execution and demand. The company’s India volumes grew by 14.4%, and international volumes by 21.4%. The integration of Twizza is expected to further supercharge this long-term international expansion.

While VBL has almost no direct business in the Middle East conflict zones, it isn't totally immune. Since 80% of its volume comes from India, the main risk is secondary, specifically the cost of petroleum-based PET bottles and global logistics. Chairman Ravi Jaipuria emphasized that a "safety net" of strategic inventory management is in place to handle supply chain turbulence.

Management plans to invest between Rs 500-600 crore in CY26 to keep its growth engines humming. Ravi Jaipuria credited the company's momentum to a healthy demand and disciplined execution across all its territories. However, he noted that VBL’s India realisations dipped 1.5% and termed it a strategic choice to attract new customers through larger packs and targeted price-point launches. Jaipuria described these moves as a “conscious near-term trade-off” aimed at “expanding the consumer funnel”.

Motilal Oswal retained a ‘Buy’ rating on VBL and raised the target price to Rs 600. The brokerage expects a sizzling June quarter, thanks to the El Niño heatwave and the consolidation of the Twizza and Crickley brands. With the company also aggressively scaling its snacking business, the brokerage sees a clear path for continued growth.

2. Sun Pharmaceutical Industries:

This pharma giant’s stock surged 7% on April 27 after it announced an $11.8 billion deal to buy New Jersey-based Organon. The deal marks its entry into women’s healthcare and biosimilars, while expanding its presence to over 140 countries.

MD Kirti Ganorkar sees China as the biggest prize. He said, “Sun Pharma currently has a negligible presence in China, which is the world’s second-largest pharmaceutical market at around $150 billion and is growing at 5–7% annually.” Organon provides an established $800 million Chinese operation with eight key brands, offering immediate access and lowering expansion risks.

To pay for the deal, Sun Pharma will spend up to $2.5 billion of its own cash and borrow nearly $9.8 billion. This massive loan wipes out the company’s current debt-free status. Its net debt will be about 2.3 times its earnings (EBITDA), which could curb its appetite for more big deals.

A key concern is Organon's $8.5 billion in existing debt, which Sun Pharma will inherit. Executive Chairman Dilip Shanghvi highlights a clear gap: Sun Pharmaceutical Industries has delivered strong growth, while Organon has seen flat revenue over the past five years. The success of the deal now depends on reviving growth. With only about one-third of Organon’s portfolio expanding, Sun Pharma will need to maximise returns from its mature brands to support debt repayment.

Trendlyne’s Forecaster projects strong future growth, with revenue seen rising 12.1% and net profit 28% YoY by Q4FY26. Once the deal closes in 8-9 months, Sun Pharma's revenue will nearly double to $12.4 billion, placing it into the global top 25 pharma companies.

Following the news, ICICI Direct downgraded the stock to ‘Hold’. The brokerage cites caution, noting that while Sun Pharma is skilled at acquisitions, this is its biggest bet yet. Analysts worry about execution risks and limited immediate growth drivers. On the plus side, Organon has stronger profit margins than Sun Pharma. 

3. Coal India:

This coal mining company surged 8.4% over the past week after reporting its Q4 results. Revenue grew 23.6% YoY, while net profit rose 13%, with both metrics comfortably beating Forecaster estimates. While coal volumes declined marginally in FY26, the medium-term outlook remains intact, with the company targeting a billion tonnes of coal production by FY29.

Union Coal and Mines Minister G. Kishan Reddy said, “India's rapidly growing economy requires a balanced energy strategy, with nearly 400 billion tonnes of coal reserves, among the highest globally,” underscoring coal’s share of over 70% in the current electricity mix. With a dominant ~74% share in domestic coal production, the company remains well positioned to benefit from this. Rising power demand, lower coal exports from Indonesia, and higher global gas prices are providing additional tailwinds.

To capitalise on this demand, the company has sanctioned 117 mining projects with a combined capacity of 979 million tonnes, backed by a capex outlay of around Rs 1.4 lakh crore.

EBITDA margins for the quarter stood at 27.3%, with per tonne realisation increasing 7.4% to Rs 636. The e-auction segment continues to be the most profitable, with a 11% contribution to volumes. Analysts expect the e-auction share to rise to around 15% by FY28, supporting profitability. While premiums over fixed supply agreement (FSA) prices moderated, improving global coal prices and supply disruptions linked to geopolitical tensions could support higher realisations.

The company is also diversifying beyond coal to strengthen long-term growth. It is investing in coal gasification projects with BHEL and GAIL, while expanding into thermal and renewable power. It is also exploring critical mineral assets, including rare earth elements.

ICICI Direct reiterates its ‘Buy’ rating with a higher target price of Rs 550. The brokerage expects growth driven by volume expansion, strong cash flows, and diversification into new energy segments. It also highlights the company’s net cash-positive balance sheet, supporting a dividend yield of around 6%.

4. Zensar Technologies:

This software company fell 11.4% in the past week after MD & CEO Manish Tandon guided for flat EBIT (operating) margins in Q1FY27. “Zensar’s technology, media & telecommunications (TMT) business will remain under pressure for the next few quarters,” Tandon said.

In Q4FY26, the company’s revenue grew by 6.7% YoY to Rs 1,450 crore, led by its banking & financial services segment and supported by AI-led work. But this was offset somewhat by a decline in the TMT segment, which contributed to over 18% of its total revenue during the quarter, as global tech clients cut spending and shifted more work in-house.

Net profit rose 19.4% to Rs 210 crore. However, operating performance was weak. EBIT margin declined 137 bps sequentially to 14.7%, as the company incurred upfront costs for a $210 million deal and saw lower employee utilisation during the quarter. This deal, the largest in the company’s history, is now central to its near-term growth. Tandon pointed to general delays in deal closures, noting that the deal was expected earlier but closed only in February, limiting its contribution in Q4FY26. 

CFO Pulkit Bhandari also noted that the deal will begin contributing from Q1FY27, but “full ramp-up is expected only by Q3.” That leaves growth in the next couple of quarters dependent on execution, even as core demand remains uneven. 

Competition is also intensifying. Tandon noted that larger IT firms are now bidding for smaller deals, increasing pricing pressure across the sector. AI is helping Zensar win deals, but much of this work is replacing existing services rather than adding new revenue streams.

Axis Direct maintained its ‘Hold’ call on the stock, with a lower target price of Rs 580. The brokerage expects growth to remain moderate and has cut revenue estimates for FY27 and FY28, factoring in slower deal conversion and execution timelines. 

5. IDFC First Bank: 

This private bank stock climbed 4.5% on April 27 after reporting healthy Q4FY26 results. Revenue grew 12.1% YoY, supported by strong performance in both retail and wholesale banking segments. Net profit rose 4.9%, aided by lower provisions, a Rs 129.6 crore tax refund, and improving asset quality. While profit beat Forecaster estimates, revenue came in slightly below expectations due to a slowdown in treasury operations.

Loan growth remained strong, driving net interest income (NII) higher. Growth was led by segments such as vehicle, gold, small business, and wholesale lending. However, deposit growth lagged due to lower savings rates, tight system liquidity, seasonal withdrawals, and the impact of a one-time fraud-related loss at a Haryana branch.

The bank reported a net interest margin (NIM) of 5.9%, in line with guidance, supported by a lower cost of funds and a higher share of retail loans. Looking ahead, management expects NIM to moderate slightly to around 5.8% as the bank increases its exposure to wholesale and business banking segments, which typically carry lower yields. Ongoing branch expansion may also weigh on margins in the near term.

CFO Sudhanshu Jain outlined the growth outlook, stating, “We expect our core income (NII and fees) to grow around 18% in FY27, driven by normalisation in stressed segments and continued traction in retail and small & medium enterprise lending.” Despite some margin pressure, management remains focused on sustaining overall profitability and maintaining prudent risk-adjusted returns.

Following the results, ICICI Direct retained its ‘Buy’ rating with a target price of Rs 80, a 14.9% upside. The brokerage expects improved operating leverage and lower credit costs to support earnings, with NII and net profit projected to grow around 19% and 80% annually over FY27–28.

Trendlyne's analysts identify stocks that are seeing interesting price movements, analyst calls, or new developments. These are not buy recommendations.